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1,3-Butadiene (CAS no. 106-99-00) is
used for the production of styrene-butadi-
ene rubber. In 1987 more than 5 billion
tons ofbutadiene were produced worldwide
(1). In the Netherlands the yearly produc-
tion is between 400,000 and 500,000 tons
(2). Butadiene has been detected in ciga-
rette smoke (3) and automobile exhaust (4)
and is currently listed as one ofthe 189 haz-
ardous air pollutants in the 1990 Clean Air
Act Amendments (5). Butadiene is carcino-
genic in mice (6). In this species, increased
incidence of lung carcinoma, hemangiosar-
coma of the heart, lymphoma, and bone
marrow atrophy were observed (6). The
carcinogenicity of butadiene in the rat was
much less pronounced (7,8). Epidemi-
ological evidence for human carcinogenicity
is inconclusive, but leukemia and lym-
phomas are considered to be two of the
largest risks (2). The toxicity ofbutadiene is
attributed to its reactive metabolites 1,2-
epoxybutene-3 and 1,3-diepoxybutane,
which were also found to be carcinogenic
in mice (9,10). Butadiene monoxide is
formed by microsomal activity in the lung
and liver of mice, rats, monkeys, and
humans. There are, however, large inter-
species differences in the ratio between lung
and liver microsomal activity (mice > rats >
humans/monkeys) (11,12).
These interspecies differences in kinet-
ics interfere with conventional methods
used to extrapolate data from animals to
humans. Toxicokinetic models containing
the relevant differences in physiological
state and metabolic activity can overcome
problems imposed by species differences. In
recent years, toxicokinetic models have
been developed rapidly (13). In this study
we describe a model for the uptake, distrib-
ution, and metabolic degradation of buta-
diene in mice. The accuracy of the model
was verified by simulating experimental sit-
uations described in the literature. Most of
these studies were carried out with the
closed-chamber technique (14), measuring
uptake of an organic vapor by animals
placed in a gas-closed chamber. After simu-
lating exposure to various ambient air con-
centrations of butadiene, both the amount
ofbutadiene present in the respective body
compartments and the amount of butadi-
ene monoxide formed in liver and lung
were evaluated. The object of this study
was to investigate whether the relative
importance of lung and liver metabolism
changes at different exposures to butadiene.
Due to differences in intraorgan concentra-
tions, lung metabolism could well be satu-
rated at lower exposure concentrations than
liver metabolism. This would have conse-
quences for low-dose extrapolations based
on in vivo studies performed at doses above
the saturation level for alveolar metabolism.
Our data demonstrate that an important
shift in the relative importance oflung and
liver metabolism may in fact occur at cur-
rent occupational exposure levels.
Methods
Lung gas exchange, distribution, and meta-
bolic clearance ofbutadiene were analyzed
by a physiological toxicokinetic model
(Fig. 1). Figure 2 is a schematic representa-
tion of the process ofmodel development.
The outline for the mathematical descrip-
tion of the model was adapted from the
model for styrene described by Ramsey
and Andersen (15). In our model, gas
exchange occurs in the alveoli of the lung;
metabolism occurs both in the alveolar and
the bronchial areas of the lung and in the
liver. Metabolic activity in the three other
compartments-muscle, fat, and the ves-
sel-rich compartment-is neglected. The
bronchial, not respiratory, part ofthe lung
was incorporated in the model to conform
to the physiological blood flows. In the
alveoli, two processes occur. Gas exchange
can be described by the mass balance for-
mula (See Table 1 for an explanation of
the symbols used):
QalvCair + QpuCv,tot = QalvCexh
+QpUCvi,tot. (1)
Assuming balance between exhaled air
and the blood leaving the gas exchange
region:
C _Cvi,pu Cexh =
Pbl,air
This can be combined to:
Cvi,pu = QalvCair + QpuCv,tot
QalvPbl,air+Qpu
(2)
(3)
Next, distribution over pulmonary
(alveolar) tissue and metabolism therein
can be described by:
dApuldt = Qpu CVi,pU -Cv,pu)
Vmax,pu XCv,pu.
Km+Cv,pu
(4)
The bronchial part ofthe lung receives
arterial blood from the left side of the
heart,
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Table 1. Explanation ofthe symbols used
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d4*r/dt = Qbr(Cart -Cv,br)
Vmax,br XCv,br
Km+Cv,br
The arterial blood is a mixture of the
blood returning from the alveoli and the
bronchi ofthelung:
QtotCart =QpuCv,pu +QbrCv,br, (6)
while the summation ofthe two blood-
streamsgives the total cardiac outputofthe
left heart side (16)
Qtot =Qpu +Qbr. (7)
Distribution and metabolism in the
liver can be described in the same way as in
thelung areas:
dAi/dt
= Qi(Cat
- Cv,li)
Vmax,li XCv,Ii (8)
Km+Cv,ji
Thechange in the butadiene concentra-
tion in the nonactive compartments can be
describedby:
d4xldt
=Qx(Cart
-Cv,x) . (9)
The venous concentration leaving an
organ is thought to be in equilibrium with
the concentration in the organ [well-stirred
model (17)1:
CV,X=Cx/Px,bI. (10)
Finally, the total amount of butadiene
returning from the main circulation and
leaving the right heart chamber toward the
lung is described by:
QpuCv,tot =QiCv,ii +QCv,f
+QvrCv,vr +QnCv,m ( 11)
For validation purposes, the model was
extended with the equation necessary to
evaluate the changes in air concentration in
a closed chamber containing n animals
(18):
dCair/dt = nQalv/Vair
(Cvi,pu/Pbl,air-Cair) .(12)
The model was coded for computer
simulations with our simulation package
Chrisis (19). Parameters for simulation
experiments were included in separate
batch files. Simulations were executed on
anAtari TT030workstation.
Ax Amountof butadiene in compartmentx
BMOX Butadiene monooxidase activity per gram
tissue x
Cair Butadiene concentration in inhaled air
(equalto concentration in closed cham-
ber)
Cart Butadiene concentration in arterial blood
(blood enteringthe main body compart-
ments)
Cexh Butadiene concentration in exhaled air
C,ijp, Intermediate butadiene concentration in
the pulmonary blood aftergas exchange
and before distribution and metabolism
C,tot Butadiene concentration in venous blood
aftermixing
Cvx Butadiene concentration in blood leaving
compartment x
CX Butadiene concentration in compartment
Km
n
Pbl,air
Px,bl
0alv
Qtot 40
ax
t
vmax,x
V
Xbr
Xf
xIi
lIu
Xm XMu
XPU
X.r
x
Michaelis constantfor metabolic removal
ofbutadiene
Number of animals used in an experiment
Partition coefficient blood/air
Partition coefficient between compart-
mentxand blood
Alveolarventilation
Cardiac output
Bloodflowthrough compartmentx
time
Maximum metabolic rate in compartment
x
Volume of compartmentx
Value of parameterxinthe bronchial part
ofthe lung
Value of parameterxinfattissue
Value of parameterxinthe liver
Value of parameterxinthe lung
Value of parameterxin muscletissue
(lean bodymass)
Value of parameterxinthe pulmonary
(alveolar) region ofthe lung
Value ofparameterxin vessel-richtissue
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497Physiological data for alveolar ventila-
tion, blood flows, and organ volumes for
mice (Table 2) were published by Travis
(20) and were adjusted for the actual ani-
mal weight using the allometric scaling
formulas as published by Fiserova (17).
The fractional volumes and blood flows
for the two separate lung compartments
were taken from Greep and Weis (16).
We estimated the tissue-blood partition
coefficients and the blood-air partition
coefficients used in the model by means
of regression analysis of published data
(21-23) (Table 3). We obtained the tis-
sue-blood partition coefficients by inter-
polation from linear regression analysis of
the tissue-blood partition coefficients on
the log-transformed octanol-water parti-
tion coefficients. To obtain the blood-air
partition coefficients, multiple linear
regression analysis was performed on the
independent variables octanol-water par-
tition coefficient and vapor pressure after
logarithmic transformation of dependent
and independent variables. We calculated
the ratio in maximum metabolic activity
between liver and lung from the butadi-
ene monooxidase (BMO) activity in post-
mitochondrial preparations of NMRI
mice determined by Schmidt and Loesser
(12), using (24):
Vmax,pu
=Vmaxj,i (BMOIu/BMOli
xvi./vli). (13)
Recently, Csanady et al. (11) found
that the metabolic rate of butadiene in
B6C3F1 mice, used in the closed-chamber
study and carcinogenicity tests, is higher
than thevalue Schmidt and Loesser report-
ed for NMRI mice (12). They expressed
0 5 10 15
Time (hr)
Figure 3. Model simulations of the disappearance of butadiene in a gas-closed chamber occu-
pied by mice. The open circles show the results of a closed-chamber study with male B6C3F1
mice (n = 8, mean body mass 27.5 g, chamber volume 6.41) carried out by Kreiling et al. (25). The
lines showthe results for model simulations of equal conditions (i.e., mice exposed to 4800, 2000,
1000, 500, 200, and 100 ppm butadiene). Metabolism in the alveolar and bronchial areas was set in
accordance to the relative volumes.
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Table 2. Physiological values for mice and rats
and partition coefficients for butadiene used in
the simulations and references
Mice Rats
Body mass(kg) 0.0275(25) 0.215(27)
Alveolar ventilation 24.5(17,20) 118.7(17,201
Blood flows(ml/min) to:
Liver 6.14(17,201 19.17(17,201
Fat 2.34(17,201 6.52(17,201
Muscle 3.81( 17,20) 11.13(17,201
Vessel-rich tissue 10.75(17,201 33.60(17,20)
Bronchial lung area 1.79(16,17,201 5.514(16,17,201
Calculated fromthe above:
Alveolarlung area 23.04 70.42
Cardiac output 24.83 75.93
(left heartchamber)
Volumes(ml):
Liver 1.65(17,201 8.63(17,20)
Fat 2.94(17,201 14.0(17,201
Muscle 19.09(17,201 162.7(17,201
Vessel-rich tissue 1.17(17,201 9.49(17,201
Bronchial lung area 0.2(16,17,201 1.29(16,17,201
Alveolar lung area 0.18(16,17,20) 1.63(16,17,20)
lime (hr)
Figure 4. Model simulations of the disappearance of butadiene in a gas-closed chamber occu-
pied by rats. The open circles show the results of a closed-chamber study with male Sprague-
Dawley rats (n = 2, mean body mass 215 g, chamber volume 6.41) carried out by Bolt et al. (27).
The lines show the results for model simulations of equal conditions (i.e., rats exposed to 4500,
2500, 1200, 450, 200, and 100 ppm butadiene). Metabolism in the alveolar and bronchial areas was
set in accordance tothe relative volumes.
doubt (11) about whether the reported
values were true V.. values. Because we
only used the ratio of the lung and liver
values, this discrepancy is not likely to
affect the outcome ofour simulations.
The whole-body maximum metabolic
activity, the affinity constant for the
metabolic activity (Km), and the most
probable distribution of lung metabolic
activity over the alveoli and the bronchial
area were derived from model optimiza-
tion with respect to the results of the
closed-chamber study described by
Kreiling et al. (25). Finally, we compared
the model with the optimized values for
metabolic activity to independent litera-
ture data (26) and used it for further sim-
ulation studies (Fig. 2).
Results
Determination ofMetabolic
Parameters
Figure 3 shows the results of simulations
mimicking the closed-chamber studies with
Table 3. Partition coefficients (for both species)
Blood/air' 1.184, 0.603(38)
Fat-blood 32.362
Liver-blood 2.675
Muscle-blood 1.871
Kidney-blood 1.690
Lung-blood 1.272
Brain-blood 2.355
Vessel rich-bloodb 2.02
aMean value used.
bMean value of kidney-blood and brain-blood.
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Figure 5. Ratios between total lung and liver metabolite formation in mice after an 8-hr exposure to
different concentrations of butadiene. The ratios were calculated from the metabolites formed in the
lung and the liver during an 8-hr exposure to 1, 50, 100, 200, 600, and 1000 ppm butadiene as calculat-
ed by model simulation.
1.4 B
~~~* .~~~~~ *~~~Liver
flLung
~~~~~ 0 ~~~~~~~~~Bronchi
Ei 12 g
E
c-:
X..
8.4
'' M
U~~~~~~
Butadiene Exposure (ppm)
Figure 6. Metabolite formation in lung, lung parts, and liver of mice exposed to butadiene.
Metabolites formed during an 8-hr exposure of mice to 1, 50, 100, 200, 600, and 1000 ppm1butadiene
calculated by model simulation at a Kmvalue of2pM and the ideal Vmax of465 pmol hr kg-
ratio for butadiene and compared it to the
results of a study independent from the
one used for optimization of the model
parameters. The calculated whole-body
extraction ratio was 8.4%, whereas Dahl et
al. (26) reported avalue of12.8%.
Rat Model
After substitution ofthe model with physio-
logical (Table 2) and metabolic (Table 4)
parameters appropriate for the rat, a reason-
able fit with experimental closed-chamber
study results for Sprague-Dawley rats, as car-
ried out by Bolt et al. (27), was obtained
(Fig. 4). Unfortunately, in the latter study
rat weight was only given as a broad range
(150-280 g). Because actual results of the
simulations depend largely on animal
weight, itwas not possible to do a rigid test
on the parameters used. Recently, Laib et
al. (28) carried out gas-uptake studies with
Sprague-Dawley rats to evaluate kinetic
interactions between 1,3-butadiene, and
styrene. For 1,3-butadiene, a V ax value
was found to be 230 ± 10 pmol.hr- -kg1.
This Vmax corresponds with the V ThisVmax I~~~max reported by Bolt et al. (220 pmol.hrf kg-
). With our model we found a best fit
using a Vm1 of200 pmol-hr1-kg , which
does not fall within the range the experi-
mental error of Laib et al. (28) allows.
Differences between the experimental and
our simulated data were largest at high
exposure. Some improvement for these
curves could be obtained by using even
lower Vm. and Km values. Finally, the rat
model was validated using the study by
Dahl et al. (26). The parameters were
adjusted for the weights of the rats used,
and the results were calculated. The model
calculated a whole-body extraction rate of
5.2% compared to 4.3% found by Dahl et
al. (26).
Lung/Liver Ratio ofMetabolic
Activities
Figure 5 shows how the ratio between total
lung and liver metabolic activity in mice
depends on the ambient air concentration.
The data are the model calculated ratios
for metabolites formed after 8 hr when
B6C3F1 mice carried out by Kreiling et al.
(mean body mass 27.5 g, eight animals per
chamber of 6.4 1) (2-5). This best fit was
obtained after optimization ofmodel para-
meters, which are listed in Table 3.
The total maximal metabolic activity
was determined from simulations of
closed-chamber experiments with an air
concentration starting at 4800 ppm. The
ratio between liver and total lung metabo-
lism was calculated as described in Meth-
ods. To find the most likely distribution of
the metabolism within the lung, the fol-
lowing simulations were carried out: 1) all
metabolism located either in the alveolar or
bronchial areas, 2) an equal amount of
metabolic activity in each ofthe two com-
partments, and 3) a distribution of the
metabolic activity according to the relative
volumes ofthe compartments. The best fit
with the literature data was found using
the last approach. We used the values of
metabolic parameters found in this way for
further studies.
Validation
To validate the model and its estimated
parameters, we calculated the extraction
Table 4. Metabolic parameters for mice and rats
found by optimization of the model toward litera-
ture data
Mice Rats
vmaxtot(pmol-hr1-k9g1) 465 200
Vmaxili(pmol-hr'Ikg'1) 318 171
Vmaxbr(pmol hrk1-kg-1) 77 13
Vmaxpu (pmol hr_1-kg_1) 70 16
Km(pM) 8 5
Where Vmaxx is the maximum rate of metabolic
butadiene removal for tissue x, tot, li, br, and pu
stand for total, liver, bronchial, and pulmonary
(alveolar), respectively. Km is the Michaelis con-
stant.
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Figure 7. Ratios between total lung and livermetabolite formationwith rat(A) and human(B) metabol-
ic conditions after exposure to butadiene. To examine the species differences among mice, rats, and
humans, the same physiological parameters were used as for mice exceptthat species-specific val-
ues were taken for the ratio between lung-liver metabolism and V . For rat metabolism the lung-
liver ratio used was 0.5 and the value of Vmax was 200 pmol-hr.kg . For human metabolism these
values were 0.15 and 237 pmol hr1 kg', respectively. Simulation results were calculated for the
ratios between total lung and liver metabolic activity after continuous exposure to constant air con-
centrations of 1,50, 100, 200,600, and 1000 ppm butadiene.
mice were exposed continuously to 1, 50,
100, 200, 600, and 1000 ppm butadiene.
Sensitivity analyses revealed that fitting the
model to the experimental closed-chamber
study is relatively insensitive to errors in
the Km value. A reasonable fit could still be
obtained at Km values 6 pM higher and
lower than the optimal Km value. There-
fore, the ratios for lung and liver metabo-
lism were calculated not only for the ideal
Km of 8 pM but also for 2 and 14 pM. In
all cases the ratio between lung and liver
metabolism increased when the exposure
concentrations decreased below 1000 ppm.
This increase was mostpronounced in sim-
ulations using the lowestKmvalues, but for
the Km value of8 pM there was still a 40%
increase between the values calculated at
1000 ppm and those calculated at 1 ppm.
Figure 6 shows the rate of metabolite for-
mation under these conditions in the sepa-
rate compartments: liver, total lung, and
the bronchial and alveolar areas. As Figure
6 is meant to clarify the phenomenon
shown in Figure 5, the low Km value of2
pM is used.
Little metabolite formation was obs-
erved in the bronchi. At concentrations
below 600 ppm, the largest fraction ofthe
metabolites was formed in the lung. At
higher concentrations the relative impor-
tance of liver metabolism increases due to
saturation of metabolism in the alveolar
area. At low butadiene concentrations, a
strong first-pass effect occurs in the lung.
The extraction ratio for the total lung was
45% after a 1-hr exposure at 1 ppm with
Km= 2 pM and 14% with Km= 8 pM.
Figure 7 shows the results ofsimulations in
which the distribution ofmetabolic capaci-
ty between lung and liver and the VKa.
were changed to the values for rats and
humans as published by Schmidt and
Loesser (12) and Csana'dy et al. (11),
respectively. For rat metabolism, the
lung/liver ratio used was 0.5 and the value
of Vm. was 200 pmol hr- kg-. For hu-
man metabolism, these values were 0.15
and 237 pmol.hrf kg1, respectively. The
simulations were executed with the ideal
Km of 8 pM for mice as well as for 2 and
14 pM. Simulation results were calculated
for the ratios between total lung and liver
metabolic activity after continuous expo-
sure to constant air concentrations of 1,
50, 100, 200, 600, and 1000 ppm butadi-
ene. The results in Figures 5 and 7 give a
first impression ofspecies differences in the
metabolism of 1,3-butadiene. In all situa-
tions studied, the ratio between lung and
liver metabolite formation decreased at
increasing exposure. In rat and human sit-
uations, however, simulations revealed that
hepatic metabolism exceeds lung metabo-
lism in all conditions (ratio < 1). In Figure
8 the metabolites formed in the individual
organs at a Km of 2 pM are shown. This
shows that the lower metabolite formation
in the lung is primarily caused by lower
metabolite formation in the alveolararea.
Discussion
The model described here predicts the
uptake, distribution, and metabolic clear-
ance of inhaled butadiene in mice. To
obtain a good agreement between the liter-
ature data and simulation output, it was
necessary to take into account the bifurcat-
ed blood supply of the lungs. After opti-
mization of the model parameters for
metabolic activity, the results obtained by
computer simulation were in good agree-
ment with the experimental data published
by Kreiling et al. (25). The extraction ratio
found by Dahl et al. (26) was about 30%
lower than the value calculated from our
simulations. This difference can be well
accounted for by differences in animals
and experimental conditions between the
studies used for fitting and validation.
Bond et al. (29) found depressed butadiene
metabolism in lung microsomes from mice
Environmental Health Perspectives 500A * * 1- 9*U 9.; 9 [l Ii .* ^fIMll i -
= jiW!Z.urSf= *~~~~~~~~~~~~~~~V: Bronchi
C B V Alvol
-S~~~~~~~~~~~~4
E . 12 'g'= g---',4* 43 *~Bronch a
. 4 @0 i&_4~--- e~4
Butadiene Exposure (ppm)
Figre . etaolie ormtin i lug,lun pats an lverwit rt () ad uma () mtabli,codi ti a o u S r hr hi s
and the ratio between lung and l
C -'-4----'-- Butadi4ns Exosr -'-ppm4'-) -
-~~~~ -~~~~ ---- 9...................... -1 - ' V......-....... 4 *4 "4 4* 4~
1E
B ~~s~ ~ ' ~ V '
-- ~~~~~~'~~~~4' 44' -4 ~ ~ ~ ~ ~ ~ ~ Lie
-- 4~~~~ '4'C9'49'7--4---,4 ~ ~ ~ ~ ~ ~ ~ ~ ~~un
4444* -= ~~~~~~~~~~~~~ roch E ~~~~''- 444'-<- --- *
-44'4~~~444~~45'5'~~ 444~~ - ~ ~ VAlveol cm ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~-- 4--- E~~~~~~~~~~~~~~~~,--
.......~- .........4..........
0.2~~~~~~~~~~~~ ~ '-~4-
log 444,5.444 X 4< 44 '4.>40 '4-K4', 404 44
Bu 9d'nExposure -(ppm) ->-j~544
Fiue8eaoiefraini un,ln at,adlvrwt a ()adhm n()m tblccni
tos afe xpsr't uadee Simuatin reult shw using ra-and5 huma-spc ifi vlus fr- -a
anterai btee un ndlve etblimataKmo 2-pM4-Conditions4~ were<4 th- a ea i iue7
and rats repeatedly exposed (5 days, 6
hr/day) to high concentrations (740 and
7600 ppm, respectively) of butadiene. If
this phenomenon did occur during the
closed-chamber studies, overestimation of
butadiene removal after longer exposures at
high concentrations is expected. Although
this is consistent with the fact that the cal-
culated line for butadiene left in the cham-
ber in the experiment starting at 4800 ppm
(Fig. 3) bends below the experimental val-
ues at exposure times exceeding 12 hr, the
effect seems to be ofminor importance for
the exposure times used.
After substitution of relevant rat para-
meters (Table 2) into our model, simula-
tions were in reasonable agreement with
experimental data in rats from a closed-
chamber studypublished by Bolt et al. (27.
At higher concentrations, deviations be-
tween experimental data and simulation
results still exist. An important reason for
these deviations is the relatively fast disap-
pearance ofbutadiene after longer exposure
times (>6 hr) at high starting concentrations
(2500 ppm and higher) in the closed-cham-
berstudy. In fact, the disappearance atequal
remaining chamber concentrations is faster
than what was found for studies starting at
lower concentrations. This indicates that
some kind ofinduction ofmetabolism may
have occurred. (Note that this effect is
opposite to the depression after prolonged
exposure described above.) The description
ofthe experimental conditions in the litera-
ture was inadequate for rigid control ofthe
simulation results. For this reason, no fur-
ther simulations were done with the rat
model, although calculated whole-body
extraction ratios were in good agreement
with those reported byDahl et al.
Butadiene is metabolized both in vitro
by rat, mouse, and monkey liver and lung
postmitochondrial preparations (11,12,
29-32) and in these animals in vivo (26,33)
to 1,2-epoxy-butene-3 (butadiene monox-
ide, vinyl oxirane). This reactive epoxide
can be hydrolyzed to 3-butene-1,2-diol by
epoxide hydrolase; it can also be oxidized
further to di-epoxy-butane (34) by cyto-
chrome P450-dependent activity, and it
can be conjugated with glutathione (35).
Kreuzer et al. (31) detected no NADPH-
dependent metabolism of butadiene mon-
oxide in microsomes from mice, rats and
humans. Csana'dy et al. (11) found that
formation of diepoxybutane from butadi-
ene monoxide could be quantified only in
mouse liver microsomal systems. They also
reported that enzymatic hydrolysis is high-
est in human liver tissue compared to mice
and rats, whereas capacity for glutathione
conjugation is highest in mice. Further-
more, Csana'dy et al. found butadiene
monoxide formation in human lung (n
=12) microsomes, in contrast to Schmidt
and Loesser (12), who did not detect any
butadiene monoxide in analogous prepara-
tions of one subject. Recently, Dahl et al.
(36) reported that the concentrations of
total 1,3-butadiene metabolites in the
blood of monkeys were 5-50 times lower
than in mouse and 4-14 times lower than
in rats. Therefore, species differences in the
activity and localization of the formation
of this activated metabolite might be
important for riskevaluation.
The results of our simulations show
that in mice the relative importance of
metabolite formation in the lung is higher
than would be expected solely from the
distribution ofthe metabolic activity. This
is especially true at lower (< 200 ppm)
exposures. The cause for this phenomenon
lies in the strong first-pass effect in the
lung, which results in much higher con-
centrations in alveolar tissue than in all
other tissues. At 1 ppm exposure and with
a Km of2 pM, the concentration in alveo-
lar tissue was six times higher than in liver
tissue, and for a Km of 8 pM it was still
two times higher. In addition to this first-
pass effect, the high blood flow to the alve-
olar area also contributes to the importance
oflung metabolism. When the distribution
between lung and liver metabolism was
changed to the values published for rats
and humans, a shift to higher relative
importance of lung metabolism at low
doses was also found. However, although
the shift in mice made the lung the most
important metabolic organ at low expo-
sures, this was not so in the rat and human-
like situations. In mice the lung/liver ratio
Volume 101, Number6, November 1993 501shifted from 0.67 to 1.19 at a Km of 8 pM
and from 0.82 to 4.89 at a Km of2 pM. In
simulations using human parameters for
metabolism, these shifts were from 0.047 to
0.102 and from 0.053 to 0.27, respectively.
The relatively high rate ofactivation found in
the lungs ofmice might be responsible forthe
appearance oflung carcinoma and could also
contribute to the formation ofheart heman-
giosarcoma. Therefore, our findings indicate
that the high sensitivity of mice is not only
due to species-dependent differences in meta-
bolicactivity, butalso to resultingshifts in the
relative importance oforgan-specific metabo-
lism.
The original carcinogenicity studies in
B6C3F1 mice were carried out at butadiene
concentrations of625 and 1250 ppm (5). In
more recent studies using much lower con-
centrations, increased incidences of al-
veolar-bronchiolar neoplasms in female mice
were found after 2-year exposures as low as
6.25 ppm (32). This high sensitivity to alveo-
lar-bronchiolar neoplasm formation at low
doses, as found in mice, can be explained by
the relatively high rate oflung metabolism at
low exposure levels indicated by our simula-
tion studies. In fact, two phenomena occur:
1) lungmetabolism atlowexposures ishigher
thanwouldbeexpectedfrom linearextrapola-
tion from data obtained at high exposures,
and 2) the relative importance ofmetabolite
formation in the lung as compared to that in
the liver is higher than would be expected
from findings at high doses. This could result
in a shift ofthe relative importance ofliver
neoplasms tolungneoplasmsatlowerdoses.
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